These findings suggest that treatment with the selective htr2b antagonist suppresses hyperglycemia, hyperinsulinemia, the increases in plasma FGF21 levels and hepatic FGF21, Sdf2l1, and htr2a expression in KKAy mice. The gene discussed is HTR2B; the disease is Hyperglycemia.